Jakavi is used to treat specific blood disorders and a complication after stem cell transplants. Specifically, it's used for myelofibrosis, polycythemia vera, and graft-versus-host disease (GvHD).
Here's a more detailed breakdown:
-
Myelofibrosis: Jakavi treats adults with myelofibrosis, a rare bone marrow disorder that disrupts the body's normal production of blood cells. This disruption leads to scarring in the bone marrow, severe anemia, weakness, fatigue, and often an enlarged spleen.
-
Polycythemia Vera: Jakavi is prescribed for adults with polycythemia vera who have not responded well to or cannot tolerate hydroxyurea. Polycythemia vera is another rare blood disorder where the bone marrow produces too many red blood cells, causing the blood to thicken. This increases the risk of blood clots, stroke, and other complications.
-
Graft-Versus-Host Disease (GvHD): Jakavi is used in patients 12 years and older who have acute or chronic GvHD after stem cell transplantation. GvHD is a condition where the donor's immune cells (the graft) attack the recipient's (the host's) tissues.
In summary, Jakavi (ruxolitinib) is a medication used to treat myelofibrosis, polycythemia vera, and graft-versus-host disease, all serious conditions affecting the blood and bone marrow.
